New England Journal of Medicine, 385(1), 46-58. MASSACHUSETTS MEDICAL SOC New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2021, 385 (1), pp.46-58. ⟨10.1056/NEJMoa2028631⟩ Kastritis, E, Palladini, G, Minnema, M C, Wechalekar, A D, Jaccard, A, Lee, H C, Sanchorawala, V, Gibbs, S, Mollee, P, Venner, C P, Lu, J, Schönland, S, Gatt, M E, Suzuki, K, Kim, K, Cibeira, M T, Beksac, M, Libby, E, Valent, J, Hungria, V, Wong, S W, Rosenzweig, M, Bumma, N, Huart, A, Dimopoulos, M A, Bhutani, D, Waxman, A J, Goodman, S A, Zonder, J A, Lam, S, Song, K, Hansen, T, Manier, S, Roeloffzen, W, Jamroziak, K, Kwok, F, Shimazaki, C, Kim, J-S, Crusoe, E, Ahmadi, T, Tran, N, Qin, X, Vasey, S Y, Tromp, B, Schecter, J M, Weiss, B M, Zhuang, S H, Vermeulen, J, Merlini, G, for the ANDROMEDA Trial Investigators & Abildgaard, N 2021, ' Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis ', The New England Journal of Medicine, vol. 385, no. 1, pp. 46-58 . https://doi.org/10.1056/NEJMoa2028631
CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid
Phase II Clinical Trial for Treatment of Myelodysplastic Syndromes Comparing Hydralazine / Ac.Valproico and Supportive Care in Patients Not Candidates, Refractory and / or Intolerant to Intensive Chemotherapy